Carlson, John R
[Google Scholar] [17].Tang Y, Zhang L, Zeng Y, et al
Our study showed that GLP-1 RA use in patients with T2D without viral hepatitis exhibited no significant difference in preventing liver cirrhosis development compared to GLP-1 RA no-use
Shima Hadidchi, MD, focuses on creating personalized treatment plans tailored to each individuals unique health profile, ensuring safe, steady, and sustainable results
When to extend timeline Consider using beyond 30 days when: Peptide is very expensive (TB-500, pharmaceutical GLP-1s) You're close to finishing vial (only 2-3 doses remain) Peptide appears perfect (clear, no smell, stored optimally) You're using for non-critical purpose (anti-aging vs acute injury) Financial hardship makes wasting difficult Maximum extension: 45 days for most stable peptides (BPC-157, TB-500, semaglutide)
Results Clinical Outcomes Long-term projections in patients with inadequate glycemic control on metformin with or without an SGLT-2 inhibitor indicated that oral semaglutide 14 mg was associated with equivalent discounted life expectancy and improvements in discounted quality-adjusted life expectancy of 0.18 QALYs versus liraglutide 1.8 mg in the base case analysis (Table 3)